Heron Therapeutics, Inc. (HRTX) announced on Wednesday that it has submitted a Prior Approval Supplement or PAS Submission to the FDA for Zynrelef also known as the 'bupivacaine and meloxicam' extended-release solution Vial Access Needle or VAN.
The company is expecting to receive the assigned action date for the FDA's review of this PAS in the next few weeks, with an estimated timeline of 4 to 6 months for an action date on this PAS.
If approved, the VAN will replace the vented vial spike previously used and could potentially reduce Zynrelef's withdrawal time to 20 to 40 seconds.
Zynrelef was first approved by the FDA in May 2021 and has since received approval for two expanded label sNDAs, one in December 2021 and the other in January 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.